Answer: E
– Doripenem: Non-inferior to Pip-Tazo in nosocomial pneumonia, including non-ventilated patients and early VAP pneumonia. Non-inferior to imipenem in early and late VAP
– Telavancin: Vancomycin vs telavancin in Gram-positive HAP and VAP, 1532 patients randomized. Telavancin non-inferior to vancomycin
– Tigecycline: In vitro activity versus MRSA (> vancomycin, > linezolid). Bacteriostatic, well distributed in tissues. Approved for complicated intraabdominal
infections and SSSIs. Published trials in CAP only; non-inferior to levofloxacin. Failed non-inferiority trials in VAP
– Ceftobiprole: Phase III studies in HAP due to MRSA. Broad-spectrum activity against Gram-positive and Gram-negative including MRSA and P.
aeruginosa. Non-inferior to vancomycin in SSSI. Inactive against ESBLproducing Enterobacteriaceae, and Acinetobacter baumanii
– Daptomycin: NOT INDICATED FOR PNEUMONIA. In CAP RCTs, daptomycin cure rates inferior to Ceftriaxone. Antibacterial activity inhibited by pulmonary surfactant
Reference
HKSCCM Scientific Symposium: Management of MRSA Infection